Study to assess azeliragon for refractory metastatic pancreatic cancer
A phase 1/phase 2 study will evaluate the efficacy and safety of azeliragon for patients refractory to first-line treatment for metastatic pancreatic cancer.
Azeliragon (Cantex Pharmaceuticals) is an oral once-daily therapy that inhibits interactions of the receptor for advanced glycation end products (RAGE) with certain ligands, including S100 and HMGB1 proteins in the tumor microenvironment.
The agent originally had been evaluated as a treatment for Alzheimer’s disease, and research in that population showed the agent is well tolerated.
Enrollment for the pancreatic cancer study is underway.
“We want to understand whether we can find new treatments for a disease that has an extremely poor prognosis and a lack of available treatments,” researcher Nathan Bahary, MD, PhD, division chief for medical oncology at Allegheny Health Network Cancer Institute and member of NCI’s Pancreatic Task Force, told Healio.
In this video, Bahary provides an overview of azeliragon’s mechanism of action and provides insights into the objectives of this trial.
For more information about the trial — including questions about study eligibility or enrollment opportunities — email Stephen G. Marcus, MD, Cantex’s CEO, at smarcus@cantex.com.
If your institution is launching an oncology or hematology clinical trial and you would like to inform our clinical audience about the study design and patient enrollment opportunities, email us at hematology-oncology@healio.com.
Collapse
Healio Interviews
Read more about